The anti-cancer activity of CDK9 inhibitors relies largely on the rapid turnover rate of the oncoprotein target, as well as the critical dependence of the cancer cells on the sustained expression of the oncoprotein for survival. This evidence concerns the gene CDK9 and cancer.